Status:

WITHDRAWN

Acute Bronchodilator Effects of Ipratropium/Levosalbutamol 20/50 mcg Fixed Dose Combination vs Salbutamol 100 mcg Inhaler Plus Ipratropium 20 mcg Inhalation Aerosol Free Combination in Patients With Stable COPD

Lead Sponsor:

Neutec Ar-Ge San ve Tic A.Ş

Conditions:

Chronic Obstructive Pulmonary Disease

Eligibility:

All Genders

40-120 years

Phase:

PHASE3

Brief Summary

The purpose of this study is to compare acute bronchodilator effects of Ipratropium/Levosalbutamol 20/50 mcg Fixed Dose Combination (2 inhalations) via pMDI and Salbutamol 100 mcg Inhaler (2 inhalatio...

Eligibility Criteria

Inclusion

  • Female and male patients aged ≥40 years diagnosed with symptomathic stable moderate-severe-very severe COPD: post-bronchodilator FEV1/FVC \<70% predicted and a post-bronchodilator FEV1 \<80% predicted at screen visit.
  • Group B COPD CAT: ≥10 or mMRC: ≥ 2 Exacerbation: 0-1 (not leading to hospital admission)
  • Group C COPD CAT: \<10 or mMRC: 0-1 Exacerbation: ≥2 (not leading to hospital admission) or ≥1 (leading to hospital admission)
  • Group D COPD CAT: ≥10 or mMRC: ≥ 2 Exacerbation: ≥2 (not leading to hospital admission) or ≥1 (leading to hospital admission)
  • Current or ex-smokers with a smoking history of at least 10 pack-years
  • Patients who have no exacerbation within the last 4 weeks
  • Female patients who use effective contraception
  • Patients who have a capability to communicate with investigator
  • Patients who accept to comply with the protocol
  • Patients who sign written informed consent form

Exclusion

  • History of hypersensitive to anticholinergics or SABAs
  • History of COPD exacerbation or lower respiratory track infection that required treatment with antibiotic, oral or parenteral corticosteroid within the last 4 weeks prior the screening visit or during the run-in/wash-out period or history of respiratory tract infection that required treatment with antibiotic within the last 14 days prior the screening visit.
  • Hospitalization due to COPD or pneumonia within the last 3 mounts prior the screening visit
  • Use of oral corticosteroid at unstable dosages (i.e. \<6 weeks on a stable dose of prednisone)
  • SGOT (serum glutamic oxaloacetic transaminase) \>80 IU/L, SGPT (serum glutamic pyruvic transaminase) \>80 IU/L, bilirubin \>2.0 mg/dL or creatinine \>2.0 mg/dL
  • History of asthma, significant chronic respiratory diseases (i.e., significant bronchiectasis, interstitial lung diseases, etc.) other than COPD or presence of disease that may be serious and/or potentially affect results of the study.
  • Initiation of an inhaled steroid or change in dose within \<6 weeks prior the screening visit
  • Use of beta-blocker, monoamine oxidase (MAO) inhibitor or tricyclic antidepressant within the last 30 days prior the screening visit
  • Recent (within ≤1 year prior the screening visit) history of heart attack, heart failure, acute ischemic heart disease or presence of serious cardiac arrhythmia requiring drug treatment
  • Regularly use of daytime CPAP (continuous positive airway measure) oxygen therapy for longer than 1 hour per day
  • Initiation of pulmonary rehabilitation within the 3 months prior the screening visit
  • History of lung volume reduction surgery
  • Drug or alcohol abuse
  • Presence of active tuberculosis
  • History of atopy or allergic rhinitis
  • History of cancer within the last 5 years
  • Attenuated live virus vaccination within the last 2 weeks prior the screening visit or during the run-in/wash-out period
  • Pregnancy or lactation
  • Presence of known symptomatic prostatic hypertrophy requiring treatment
  • Presence of known narrow-angle glaucoma requiring treatment
  • Currently participating in another clinical trial or treatment with another investigational study drug within the last month or 6-half-lives, whichever is longer.

Key Trial Info

Start Date :

September 3 2021

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

September 3 2022

Estimated Enrollment :

Patients enrolled

Trial Details

Trial ID

NCT04446637

Start Date

September 3 2021

End Date

September 3 2022

Last Update

September 13 2021

Active Locations (0)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 0 (0 locations)

No Results Found

We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.